Adolor Corp

Adolor — Corporate Update (December 2007)

14 slides from Adolor's corporate update, Dec 5, 2007

  1. Slide 1: Adolor/Pfizer Collaboration Delta Opioid Receptor Agonist Program

    Adolor/Pfizer Collaboration Delta Opioid Receptor Agonist Program December 5, 2007 NASDAQ: ADLR Exhibit 99.2 © 2007 Adolor Corporation. All rights reserved.

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This oral presentation and the questions and answers that follow contain forward-looking statements, including, but not limited to, statements about: • our Delta License and Collaboration Agreement with Pfizer • potential milestone payments • our collaboration plans for develop

  3. Slide 3: Adolor/Pfizer Collaboration Delta Opioid Receptor Agonist Program

    © 2007 Adolor Corporation. All rights reserved. Adolor/Pfizer Collaboration Delta Opioid Receptor Agonist Program

  4. Slide 4: Traditional Opioid Analgesics

    Traditional Opioid Analgesics One of the oldest and best known drug classes in the world Broad analgesic utility in many pain conditions - Regularly used for inflammatory, nociceptive and neuropathic pain Unprecedented depth of pain relief - Only FDA approved drugs for moderately-severe to severe pa

  5. Slide 5: Delta Opioid Receptor – a new path

    Delta Opioid Receptor – a new path Three Opioid Receptors (mu, delta and kappa) Traditional opioid analgesics are selective or predominately selective for the mu opioid receptor No FDA approved drugs are selective for delta or kappa The Delta Potential - Analgesia without some of the limiting side e

  6. Slide 6: Adolor's Delta Program Progression

    Adolor’s Delta Program Progression Jan 2003 Project initiated that led to current chemical scaffold Mar 2003 First prototype of our novel chemical class characterized as a selective delta agonist Mar 2005 ADL5859 nominated for clinical development Dec 2005 ADL5859 IND filed with the FDA Sep 2006 ADL

  7. Slide 7: ADL5859/ADL5747 Clinical Rationale

    ADL5859/ADL5747 Clinical Rationale Potent, selective and proprietary (patent application filed) Delta Agonists Favorable physicochemical properties Efficacy in inflammatory, incisional and neuropathic pain preclinical models Acceptable safety and toxicology preclinical profiles ADL5859 oral bioavail

  8. Slide 8: Adolor/Pfizer Collaboration

    Adolor/Pfizer Collaboration License and Collaboration Agreement Exclusive Worldwide Development and Commercialization of ADL5859 and ADL5747 Focus on inflammatory, acute and neuropathic pain Provisions for Adding Compounds and Indications

  9. Slide 9: Adolor/Pfizer Collaboration

    Adolor/Pfizer Collaboration Joint Committees guide development and commercialization Development Adolor: IND filings and clinical program through Phase 2a Pfizer: Subsequent worldwide development and regulatory approvals Commercialization Pfizer: Manufacture, market and sell worldwide Adolor: Co-pro

  10. Slide 10: Adolor/Pfizer Collaboration

    Adolor/Pfizer Collaboration United States Profits/Losses shared 60% to Pfizer and 40% to Adolor US development expenses (external) to be shared in same proportion Rest Of World Adolor to receive royalties on Pfizer net sales

  11. Slide 11: Upfront and Milestones

    Upfront and Milestones Adolor to receive upfront payments of $31.9 million $30 million upfront $1.9 million reimbursement for Phase 2 development costs Adolor may receive milestones of up to $155 million for the first compound and $77.5 million for a second compound Over 50% of such milestones prior

  12. Slide 12: Collaboration Clinical Development

    Collaboration Clinical Development ADL5859 Phase 2 Program 33CL230 Acute pain following third molar extraction 33CL232 Pain associated with rheumatoid arthritis 33CL231* Pain associated with diabetic peripheral neuropathy To initiate Pain associated with osteoarthritis ADL5747 IND pending Phase 1 ex

  13. Slide 13: Adolor's Strategy

    Adolor’s Strategy Rapidly advance ADL5859 and ADL5747 in pain indications Capitalize on Pfizer’s expertise in the worldwide development and/or commercialization of novel pain compounds Lyrica® and Celebrex® Adaptive structure allows for additional compounds and/or indications Lyrica and Celebrex are

  14. Slide 14: Adolor Corporation contact details

    Adolor Corporation 700 Pennsylvania Drive Exton, PA 19341 484-595-1500 w w w . a d o l o r . c o m © 2007 Adolor Corporation. All rights reserved.

Adolor — Corporate Update (December 2007) on 6ix